National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nintedanib is indicated for the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 17/07/2020
Rapid review completed 28/08/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nintedanib compared with the current standard of care.